Since the majority of human cancers display elevated glucose uptake and several targeted agents such as the BRAF inhibitor, vemurafenib, and the estrogen antagonist, fulvestrant, acutely suppress glucose metabolism in order to inhibit tumor growth [17, 27], we believe that PFKFB3 and PFKFB4 kinase inhibitors may prove effective for the treatment of cancer. The gene discussed is BRAF; the disease is neoplasm.